On December 3, 2020 Genmab A/S (Nasdaq: GMAB) reported that Janssen Biotech, Inc. (Janssen) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy (Press release, Genmab, DEC 3, 2020, View Source [SID1234572123]). This is the first BLA submission for a product candidate that was created using Genmab’s proprietary DuoBody technology platform. In July 2012, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmab’s DuoBody technology platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Today’s milestone underscores the promise of our DuoBody technology platform to effectively create innovative and truly differentiated bispecific antibody therapeutics," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

For more information related to Janssen’s amivantamab filing click here.

About Non-small Cell Lung Cancer
Lung cancer is the most common cancer worldwide. Approximately 80 to 85 percent of lung cancers are classified as NSCLC and include subtypes adenocarcinoma, squamous cell carcinoma and large cell carcinoma1,2. Mutations in the EGFR gene are common in patients with NSCLC, including 10 to 15 percent of NSCLC patients in Western countries.3,4 The five-year survival rate for all patients with metastatic NSCLC with EGFR mutations who are treated with EGFR tyrosine kinase inhibitors is less than 20 percent.5,6 In addition, the estimated median overall survival for patients with NSCLC and EGFR Exon 20 insertion mutations is shorted than in patients with common EGFR mutations.7

On December 3, 2020 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that the Company will present at the Benzinga Global Small Cap Conference taking place virtually December 8-9 (Press release, Genprex, DEC 3, 2020, View Source [SID1234572122]). Genprex’s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Benzinga Global Small Cap Conference

Presentation Date: Tuesday, December 8

Presentation Time: 2:30 p.m. EST

Registration Link: https://bit.ly/2Jf5TcN

The Benzinga Global Small Cap Conference will provide investors with direct access to small caps for insights on their leadership, business fundamentals and plans for expansion. Attending investors will also have the opportunity to meet with management of presenting companies on a one-on-one basis.

On December 3, 2020 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, reported two poster presentations at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) taking place from December 8-11, 2020 (Press release, CytomX Therapeutics, DEC 3, 2020, View Source [SID1234572121]). Abstracts are available to the public online on the SABCS website at www.sabcs.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be presenting at this key breast cancer symposium exploratory translational studies of praluzatamab ravtansine, CX-2009, as well as the design of our new phase 2 study investigating CX-2009 alone or in combination with pacmilimab, our Probody therapeutic to PD-L1, in patients with HER2-non amplified breast cancer," commented Amy Peterson, M.D., chief development officer of CytomX Therapeutics. "The phase 1 clinical data for CX-2009, previously presented and updated here, reinforce the potential for this first in class molecule to achieve clinically meaningful outcomes in patients with advanced breast cancers and our capability to leverage the Probody platform to drug previously elusive targets."

Details on CytomX’s presentations at the 2020 SABCS are below:

Title: Intratumoral Activation and Phase 1/2 Clinical Activity of CX-2009, a Probody Drug Conjugate (PDC) Targeting CD166
Poster Number: PS11-07
Presenter: Joyce Liu, M.D., Dana Farber Cancer Center
Poster Session: Poster Session 11: Systemic Therapies II – New
Poster Session Date: Wednesday, December 9, 2020: 9:00 AM ET

Title: A Phase 2, open-label study to evaluate the safety and efficacy of the probody therapeutic (Pb-Tx) CX‑2009 in metastatic HR-Positive/HER2-negative breast cancer (mHR+/HER2− BC) and of CX-2009 as monotherapy and in combination therapy with CX-072 in metastatic triple-negative breast cancer (TNBC)
Poster Number: OT-03-08
Lead Author: Kathy Miller, M.D., Indiana University Simon Cancer Center
Poster Session: Ongoing Trials Posters: Antibody-drug Conjugates
Poster Session Date: Wednesday, December 9, 2020: 9:00 AM ET

On December 3, 2020 ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, reported that Dr Tim Franklin, ImmuPharma’s Chief Operating Officer, will be presenting at the prestigious Biotech Showcase Digital 2021 (Press release, ImmuPharma, DEC 3, 2020, View Source [SID1234572116]). The event will be virtually held between 11 and 15 January 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of ImmuPharma’s participation, an on-demand Company presentation has been provided in advance to the opening of the event. This will allow registered attendees to get access to presentation material prior to the start of the showcase on 11 January 2021.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

On December 3, 2020 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, reported that the Company’s CEO Dr. Pnina Fishman will present at Benzinga’s inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 3:00 pm ET on Track 2 (Press release, Can-Fite BioPharma, DEC 3, 2020, View Source [SID1234572114]). Investors interested in viewing Can-Fite’s presentation may register with free access here for the two-day conference which takes place virtually from December 8-9, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!